BioNexus Gene Lab annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
BioNexus Gene Lab Revenue Growth & History (BGLC)
BioNexus Gene Lab reported $7.4M in revenue for fiscal 2025, a decrease of 21.93% from the previous fiscal year.
View full BioNexus Gene Lab company overviewBioNexus Gene Lab annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.4M | −$2.1M | −21.93% |
| 2024 | 2024-12-31 | $9.5M | −$260,160 | −2.66% |
| 2023 | 2023-12-31 | $9.8M | −$1.2M | −10.60% |
| 2022 | 2022-12-31 | $10.9M | −$2.4M | −18.21% |
| 2021 | 2021-12-31 | $13.4M | $2.0M | +17.31% |
| 2020 | 2020-12-31 | $11.4M | $11.3M | +8872.03% |
| 2019 | 2019-12-31 | $126,955 | −$85,373 | −40.21% |
| 2018 | 2018-12-31 | $212,328 | — | — |
BioNexus Gene Lab quarterly revenue
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $76,156 | −$2.2M | −96.63% |
| Q1 2026 | 2026-03-31 | $22,842 | −$2.1M | −98.93% |
| Q4 2025 | 2025-12-31 | $483,760 | −$2.0M | −80.83% |
| Q3 2025 | 2025-09-30 | $2.5M | −$86,553 | −3.29% |
| Q2 2025 | 2025-06-30 | $2.3M | $285,689 | +14.47% |
| Q1 2025 | 2025-03-31 | $2.1M | −$244,776 | −10.28% |
| Q4 2024 | 2024-12-31 | $2.5M | $250,788 | +11.03% |
| Q3 2024 | 2024-09-30 | $2.6M | $76,690 | +3.00% |
| Q2 2024 | 2024-06-30 | $2.0M | −$592,284 | −23.07% |
| Q1 2024 | 2024-03-31 | $2.4M | $4,646 | +0.20% |
| Q4 2023 | 2023-12-31 | $2.3M | −$566,508 | −19.95% |
| Q3 2023 | 2023-09-30 | $2.6M | −$21,400 | −0.83% |
| Q2 2023 | 2023-06-30 | $2.6M | $81,747 | +3.29% |
| Q1 2023 | 2023-03-31 | $2.4M | −$651,740 | −21.52% |
| Q4 2022 | 2022-12-31 | $2.8M | −$405,696 | −12.50% |
| Q3 2022 | 2022-09-30 | $2.6M | −$1.0M | −27.99% |
| Q2 2022 | 2022-06-30 | $2.5M | −$607,070 | −19.63% |
| Q1 2022 | 2022-03-31 | $3.0M | −$420,214 | −12.18% |
| Q4 2021 | 2021-12-31 | $3.2M | −$880,615 | −21.34% |
| Q3 2021 | 2021-09-30 | $3.6M | $484,954 | +15.69% |
| Q2 2021 | 2021-06-30 | $3.1M | $2.0M | +180.21% |
| Q1 2021 | 2021-03-31 | $3.4M | $379,133 | +12.35% |
| Q4 2020 | 2020-12-31 | $4.1M | $4.1M | +7677.50% |
| Q3 2020 | 2020-09-30 | $3.1M | $3.1M | +12687.04% |
| Q2 2020 | 2020-06-30 | $1.1M | $1.1M | +4998.25% |
| Q1 2020 | 2020-03-31 | $3.1M | $3.0M | +10830.03% |
| Q4 2019 | 2019-12-31 | $53,049 | — | — |
| Q3 2019 | 2019-09-30 | $24,173 | −$67,452 | −73.62% |
| Q2 2019 | 2019-06-30 | $21,645 | −$89,651 | −80.55% |
| Q1 2019 | 2019-03-31 | $28,088 | — | — |
| Q3 2018 | 2018-09-30 | $91,625 | — | — |
| Q2 2018 | 2018-06-30 | $111,296 | — | — |
BioNexus Gene Lab revenue growth trends
Over the last five reported fiscal years, revenue declined from $11.4M to $7.4M, a compound annual decline of 8.20%. BioNexus Gene Lab's latest reported quarter, Q2 2026, generated $76,156 in revenue, a decrease of 96.63% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BioNexus Gene Lab source filings ↗